Sionna Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$97.4MTTM through 30 Jun 2026
Free Cash Flow -$76.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-36.6%ROE
-34.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio20.05x
Net Debt-$289.9Mnet cash position
Cash & Equivalents$63.3M
Quality Metrics
Altman Z-Score7.38
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$2.15TTMFY2025: $-1.88
Dividend
No dividend
Capital Allocation
R&D Spend$72M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.